化疗引起骨髓抑制的肺癌患者的化疗前常规检查分析

Abstract
Figure/Table
References (19)
Related Citation (15)

Download: PDF (481 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective Analyze the routine examinations of lung cancer patients with chemotherapy-induced myelosuppression (CIM) caused by chemotherapy, and explore the clinical significance. Methods From January 2016 to December 2018, a total of 76 patients with successfully matched lung cancer who were admitted to the Department of Respiratory Diseases of the Second Affiliated Hospital of Fujian Medical University were retrospectively selected as the research objects. According to the presence or absence of bone marrow suppression after chemotherapy, they were divided into experimental group (38 cases, patients with CIM) and control group (38 cases, patients without CIM). The difference of routine examination before chemotherapy and curative effect after two cycles of chemotherapy were compared between the two groups. Results The levels of white blood cells, alkaline phosphatase, and neuraminic enolase in the experimental group before chemotherapy were lower than those in the control group, and the differences were statistically significant (P<0.05). In addition, the experimental group had better efficacy than the control group after 2 cycles of chemotherapy, and the difference was statistically significant (P<0.05). Conclusion Lower levels of white blood cells,alkaline phosphatase, and neuraminic enolase are more prone to CIM, and CIM is associated with better short-term clinical efficacy.

Key words： Lung neoplasms Drug therapy Toxicity Treatment outcome

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LAI Fuzhi
	DU Yuxia
	ZHOU Zhibin

Cite this article:

LAI Fuzhi,DU Yuxia,ZHOU Zhibin. Analysis of routine examinations before chemotherapy in lung cancer patients with chemotherapy-induced mylosuppression[J]. 中国当代医药, 2022, 29(6): 58-61.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I6/58

[16]	Zaleska M，Szturmowicz M，Zych J，et al.The significance of the serum tumour markers as a prognostic and predictor factors in nonsmall cell lung cancer patients[J].Pneumonol Alergol Pol，2005，73（3）：270-276.
[17]	Holdenrieder S，von Pawel J，Dankelmann E，et al.Nucleosomes，ProGRP，NSE，CYFRA 21-1，and CEA in monitoring first-line chemotherapy of small cell lung cancer[J].Clin Cancer Res，2008，14（23）：7813-7821.
[18]	Netterberg I，Nielsen EI，Friberg LE，et al.Model -based prediction of myelosuppression and recovery based on frequent neutrophil monitoring[J].Cancer Chemother Pharmacol，2017，80（2）：343-353.
[19]	Cameron DA，Massie C，Kerr G，et al.Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer[J].Br J Cancer，2003，89（10）：1837-1842.
[2]	陈万青，李贺，孙可欣，等.2014年中国恶性肿瘤发病和死亡分析[J].中华肿瘤杂志，2018，4（1）：5-13.
[4]	程凯，蒋刚.91 例化学治疗药物致Ⅳ度骨髓抑制临床分析[J].中国药业，2014，23（12）：50-51.
[6]	曹达魁，王海琴.循环肿瘤细胞、癌胚抗原及影像学对非小细胞肺癌诊断价值[J].中国现代医生，2021，59（8）：46-49，封3.
[7]	姚源山，周银杰，杨振华，等.非小细胞肺癌患者术后发生骨转移的危险因素[J].中国癌症杂志，2018，21（6）：5.
[1]	Goldstraw P，Chansky K，Chansky K，et al.The IASLC lung cancer staging project：proposals for the revision of the TNM stage groupings in the forthcoming（seventh）edition of TNM classification of malignant tumours[J].J Thorac Oncol，2007，2（8）：706-714.
[3]	Epstein RS，Aapro MS，Roy UKB，et al.Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression：Results from an Online Survey of Patients with Solid Tumors[J].Adv Rher，2020，37（8）：3606-3618.
[5]	Eisenhauer EA，Therasse P，Bogaerts J，et al.New response evaluation criteria in solid tumours：Revised RECIST guideline（version 1.1）[J].Eur J Cancer，2009，45（2）：228-247.
[8]	闫睿.化疗与靶向治疗顺序对晚期进展性非小细胞肺癌患者进展及生存期的影响[J].中国现代医生，2021，59（1）：73-76.
[9]	Emin Erbaycu A，Gunduz A，Batum O，et al.Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer：an open prospective study[J].Arch Bronconeumol，2010，46（7）：364-369.
[10]	Yashiki C，Hirose T，Sugiyama T，et al.Chemotherapy-induced myelosuppression and treatment efficacy in limitedstage disease small cell lung cancer[J].Gan To Kagaku Ryoho，2010，37（2）：245-249.
[11]	Maeda T，Ueoka H，Tabata M，et al.Prognostic factors in advanced non-small cell lung cancer：elevated serum levels of neuron specific enolase indicate poor prognosis[J].Jpn J Clin Oncol，2000，30（12）：534-541.
[12]	Shibayama T，Ueoka H，Nishii K，et al.Complementary roles of pro-gastrin-releasing peptide（ProGRP）and neuron specific enolase （NSE）in diagnosis and prognosis of smallcell lung cancer（SCLC）[J].Lung Cancer，2001，32（1）：61-69.
[13]	PetroviM，IliN，BaskiD.The value of neuroendocrine markers for response to therapy and survival in patients with advanced non-small cell lung cancer[J].Srp Arh Celok Lek，2010，138（1-2）：37-42.
[14]	Suh KJ，Keam B，Kim M，et al.Serum Neuron -Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor （EGFR）Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations [J].Clin Lung Cancer，2016，17（4）：245-252.
[15]	于亚波，丛占杰.老年非小细胞肺癌ECOG 评分、CYFRA21-1、NSE 与外科手术预后关系[J].临床与实验病理学杂志，2017，33（7）：806-808.